Best Safest Stocks To Invest In Right Now

Best Safest Stocks To Invest In Right Now: Zogenix Inc (ZGNX)

Zogenix, Inc. (Zogenix), incorporated on May 11, 2006, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. The Company's product Sumavel DosePro offers needle-free subcutaneous administration of sumatriptan for the treatment of migraine and cluster headache in a pre-filled, single-use delivery system. Its lead product candidate, Zohydro (hydrocodone bitartrate, formerly ZX002) is a 12-hour extended-release formulation of hydrocodone without acetaminophen for the treatment of chronic pain requiring opioid therapy. It completed Phase 3 development of Zohydro in 2011. Its second DosePro investigational product candidate, Relday, is a injectable formulation of risperidone for the treatment of schizophrenia. Sumavel DosePro and Zohydro are used for the treatment options available to patients and physicians in the United States. Sumavel DosePro may serve as a treatment alternative to oral and nasal triptans and offers administration when compared to traditional, needle-based sumatriptan injection. In May, 2012, it submitted a New Drug Application to the Food and Drug Administration (FDA).

The Company's collaboration with Astellas has been terminated on March 31, 2012. Sumavel DosePro is a pre-filled, single-use disposable, needle-free drug delivery system that subcutaneously delivers 6 mg of sumatriptan in 0.5 mL of sterile liquid. Sumavel DosePro is designed to be portable, intuitive and easy-to-use. To use, the patient simply snaps off a plastic tip, flips back a lever and presses the end of the delivery system to the skin of the abdomen or thigh. Under the force of a small amount of compressed nitrogen gas, the liquid form of sumatriptan is expelled out of the device as a thin jet of medication, which pierces the skin and selectively deposits into! the subcutaneous tissue.

Zogenix competes with GlaxoSmithKline, AstraZeneca PLC, Endo Pha rmaceuticals Holdings Inc., Johnson & Johnson, Merck & Co., ! Inc., Pfizer Inc., Alexza Pharmaceuticals, Inc., MAP Pharmaceuticals, Inc., Abbott Laboratories, Alpharma Inc., Endo Pharmaceuticals Holdings Inc., King Pharmaceuticals, Inc., Mallinckrodt Inc., Purdue Pharma L.P., Teva Pharmaceutical Industries Limited, Watson Pharmaceuticals, Inc., Becton, Dickinson and Company, Owen Mumford Ltd., Ypsomed, Sandoz Inc., Bioject Inc. and Antares Pharma Inc.

Advisors' Opinion:

• [By Lauren Pollock]

  The Food and Drug Administration approved an extended-release version of the narcotic painkiller hydrocodone despite a recommendation by its advisory committee that the drug should be rejected because of its potential for abuse. The federal agency approved Zohydro ER from Zogenix Inc.(ZGNX), the first hydrocodone product not mixed with milder painkillers such as acetaminophen and also the first extended-release hydrocodone product. Shares rose 15% to $3.49 premarket.

• [By Monica Gerson]

  Zogenix (NASDAQ: ZGNX) shares gained 9.21% to $3.32 in the pre-market session after the company won the FDA approval for Zohydro ER capsules.

  Ariad Pharmaceuticals (NASDAQ: ARIA) soared 5.06% to $3.74 in the pre-market trading. ARIAD Pharmaceuticals is expected to report its Q3 financial results on November 6, 2013.

source from Top Stocks Blog:http://www.topstocksblog.com/best-safest-stocks-to-invest-in-right-now-2.html